article
Utilising engineered peptides for immunotherapy
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
List view / Grid view
Immunotherapy
news
How tumours prevent formation of immune responses
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
news
Explaining uveal melanoma’s resistance to conventional immunotherapies
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
article
The immune system’s role in lung cancer risk
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
news
FOXO1 improves survival and function of CAR T cells
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
news
Link identified between bacteria and cancer treatment efficacy
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
podcasts
Breaking resistance – the future of immunotherapy in oncology
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
news
New strategies to overcome CAR T-cell resistance in AML cells
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
article
The advancement of drug-free immunotherapy
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
news
New insights into PD-1 formation could greatly improve treatments
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
article
The future of cancer immunotherapy with Elicio Therapeutics
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted…
article
Insights into cellular therapies for cancer treatment
Many exciting developments are expected to take place in immunotherapy and oncology in the next few years. We had the privilege of discussing the opportunities of various cell therapies with Dr Suresh Nair, Physician in Chief, who elucidates how Lehigh Valley Topper Cancer Institute is directing research towards better treatments,…
news
Identification of an immune biomarker for liver cancer
New immunotherapies may be developed for patients with HCC associated with steatotic liver disease, with TREM1 suggested as a target.
article
A new genetic biomarker to predict immunotherapy success
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
news
Improved CAR T-cell immunotherapy for acute myeloid leukaemia
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.